The clinical and epidemiologic consequences of redefining treatment criteria: Who should be treated?

被引:3
作者
McClung, Michael [1 ]
机构
[1] Oregon Osteoporosis Ctr, Portland, OR 97213 USA
来源
SALUD PUBLICA DE MEXICO | 2009年 / 51卷
关键词
bone density; fracture risk; osteoporosis treatment; BONE-MINERAL DENSITY; VERTEBRAL FRACTURE RISK; POSTMENOPAUSAL WOMEN; COST-EFFECTIVENESS; RANDOMIZED-TRIAL; OSTEOPOROTIC FRACTURES; NONVERTEBRAL FRACTURES; STRONTIUM RANELATE; HIP FRACTURE; DOUBLE-BLIND;
D O I
10.1590/S0036-36342009000700008
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Bone mineral density (BMD) is the tool for diagnosing osteoporosis in older adults. However, BMD alone is not sufficient for deciding who should be given treatment at either the individual patient or the public health level. Robust, scientifically validated algorithms that combine BMD with other clinical risk factors provide more accurate assessment of fracture probability. New guidelines for managing osteoporosis are now based on the assessment of absolute fracture risk, not simply on bone mineral density values. Accordingly, treatment resources will be redirected away from young postmenopausal women with low BMD and low fracture risk toward older adults at moderate or high risk for fracture. It is expected that, with these algorithms, the cost and effectiveness of medical care for patients with osteoporosis will be improved.
引用
收藏
页码:S46 / S51
页数:6
相关论文
共 58 条
[1]  
*AM ASS CLIN END, 2003, ENDOCR PRACT, V9, P544
[2]  
*AMMOM, 2000, CONS MEX OST
[3]   Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[4]  
[Anonymous], 1998, Osteoporosis Int, V8, pS1
[5]   Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].
Black, Dennis M. ;
Delmas, Pierre D. ;
Eastell, Richard ;
Reid, Ian R. ;
Boonen, Steven ;
Cauley, Jane A. ;
Cosman, Felicia ;
Lakatos, Peter ;
Leung, Ping Chung ;
Man, Zulema ;
Mautalen, Carlos ;
Mesenbrink, Peter ;
Hu, Huilin ;
Caminis, John ;
Tong, Karen ;
Rosario-Jansen, Theresa ;
Krasnow, Joel ;
Hue, Trisha F. ;
Sellmeyer, Deborah ;
Eriksen, Erik Fink ;
Cummings, Steven R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822
[6]   An assessment tool for predicting fracture risk in postmenopausal women [J].
Black, DM ;
Steinbuch, M ;
Palermo, L ;
Dargent-Molina, P ;
Lindsay, R ;
Hoseyni, MS ;
Johnell, O .
OSTEOPOROSIS INTERNATIONAL, 2001, 12 (07) :519-528
[7]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[8]   At what hip fracture risk is it cost-effective to treat?: International intervention thresholds for the treatment of osteoporosis [J].
Borgstroem, F. ;
Johnell, O. ;
Kanis, J. A. ;
Joensson, B. ;
Rehnberg, C. .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (10) :1459-1471
[9]   A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study [J].
Chesnut, CH ;
Silverman, S ;
Andriano, K ;
Genant, H ;
Gimona, A ;
Harris, S ;
Kiel, D ;
LeBoff, M ;
Maricic, M ;
Miller, P ;
Moniz, C ;
Peacock, M ;
Richardson, P ;
Watts, N ;
Baylink, D .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (04) :267-276
[10]   Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis [J].
Chesnut, CH ;
Skag, A ;
Christiansen, C ;
Recker, R ;
Stakkestad, JA ;
Hoiseth, A ;
Felsenberg, D ;
Huss, H ;
Gilbride, J ;
Schimmer, RC ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1241-1249